At the heart of this advancement lies the concept of tumor heterogeneity, which refers to the existence of multiple genetically distinct subpopulations of cancer cells within one tumor. These subpopulations differ widely in their capacity to grow, spread, and resist therapies, posing a significant hurdle for effective treatment. Conventional biopsies capture only a fraction of this diversity, often skewing diagnostic and treatment decisions. However, the Australian team, spearheaded by experts from the Olivia Newton-John Cancer Research Institute, WEHI, and Peter MacCallum Cancer Centre, has demonstrated that genetic barcoding can be harnessed to comprehensively interrogate this cellular mosaicism.

The method involves the use of lentiviruses to introduce unique DNA tags into individual cancer cells within living tumor models. Each tag functions as a “barcode,” persistently marking the cell and its progeny, thus enabling researchers to track the fate and distribution of multiple clones in solid tumors and matched liquid biopsies. This approach facilitates a longitudinal and spatial understanding of how tumor clones disseminate, evolve, and contribute to disease progression. Notably, the team applied an optimized protocol that enhances barcode labeling efficiency and recovery, ensuring robust mapping of tumor composition.

One astonishing discovery was the observation that different tumor models shed DNA into the bloodstream at varying rates, a finding that deepens our understanding of circulating tumor DNA dynamics. Despite similar cellular compositions, some tumors release copious amounts of DNA fragments into plasma, whereas others release strikingly little. This variability in DNA shedding was not simply tied to tumor size or necrosis but appeared to be model-dependent, a nuance that carries profound implications for the interpretation of liquid biopsies. Importantly, the detection of these DNA barcodes in blood samples marks the first time researchers have been able to non-invasively monitor the genetic makeup of primary tumors through circulating DNA tags.

Understanding these shedding patterns exposes a potential pitfall in existing liquid biopsy diagnostics—the prevalence of false negatives arising when tumors fail to release detectable amounts of DNA despite aggressive behavior. This model-specific shedding phenomenon calls for a recalibration of how clinicians interpret negative liquid biopsy results, emphasizing the necessity for integrating multiple surveillance methods. The differing barcode diversity found between a tumor’s core and periphery further complicates the scenario, highlighting that traditional biopsies targeting peripheral regions may underestimate the true genetic heterogeneity within a tumor.

Dr. Antonin Serrano, who led much of this pioneering research at ONJCRI and WEHI before joining the University of Melbourne’s Department of Medicine, emphasized the transformative nature of DNA barcoding technology. “Our work enabled us to quantify, with great accuracy, how much of the tumor’s cellular diversity is actually captured by both solid and liquid biopsies. This understanding is crucial for improving diagnostic precision,” he stated. The insights into the spatial variation of barcode diversity within tumors could reshape sampling strategies, ensuring that biopsies better reflect the complex biology of the disease.

Senior author Professor Delphine Merino elaborated on the translational potential of the findings. “While both liquid and solid biopsy approaches provide valuable snapshots of tumor composition, the variability between tumors suggests that a combined strategy could yield a more comprehensive picture. Such multifaceted monitoring may ultimately guide personalized therapeutic interventions, improving outcomes for patients,” she explained. The integration of DNA barcoding into clinical workflows could thus bridge the gap between molecular complexity and manageable cancer care.

Renowned breast cancer clinician Professor Sarah-Jane Dawson from Peter MacCallum Cancer Centre, co-senior author of the study, highlighted the clinical implications. “Liquid biopsies are increasingly used to non-invasively monitor how patients respond to treatment over time. By understanding the mechanisms driving differential DNA shedding among tumors, we can refine these tools to enhance sensitivity and reliability, paving the way for better disease surveillance,” she remarked. Such advancements hold promise for early detection of relapse and for tailoring therapies dynamically during treatment.

The context of this research gains urgency considering the substantial breast cancer burden in Australia, where in 2025 alone, over 20,000 new cases were diagnosed with more than 3,000 deaths reported. Improving diagnostic tools that can accurately capture tumor heterogeneity is paramount to reducing mortality rates and fostering the development of targeted therapies. This development exemplifies how molecular innovations converge with patient care to address pressing oncological challenges.

Co-first authorship was shared by Dr. Tom Weber of WEHI, reflecting the collaborative nature of this interstate effort, while co-senior authorship was also attributed to Professor Shalin Naik at WEHI. The team acknowledges support from philanthropic entities such as Love Your Sister, and from national funding bodies including the National Health and Medical Research Council and the National Breast Cancer Foundation. Their collective efforts symbolize a potent alliance between scientific innovation, clinical expertise, and community engagement.

This research, published in the peer-reviewed journal Molecular Systems Biology on February 11, 2026, sets a new benchmark for studies of tumor genetics and liquid biopsy technologies. The open DOI link offers full access to the experimental design, data, and comprehensive analysis underpinning these findings. With no competing interests declared, the work establishes an impartial and impactful contribution to cancer biology, encouraging further exploration and application worldwide.

By deploying sophisticated genetic barcoding to unravel the clonal architecture of tumors and their manifestations in liquid biopsies, Australian scientists have charted a course towards more reliable, non-invasive diagnostic tools. Such tools are critical for adapting therapeutic regimens in real time, monitoring treatment effectiveness, and ultimately improving survival rates for breast cancer patients worldwide. This innovation marks a pivotal step in personalized oncology, where the genetic fingerprint of every tumor can be traced and targeted with unprecedented clarity.

Subject of Research: Cells

Article Title: Genetic barcoding uncovers the clonal makeup of solid and liquid biopsies and their ability to capture intra-tumoral heterogeneity

News Publication Date: 11-Feb-2026

Web References: 10.1038/s44320-026-00194-w

References: Molecular Systems Biology, 2026

Keywords: Cancer, Tumor Heterogeneity, DNA Barcoding, Liquid Biopsy, Breast Cancer, Oncology, Molecular Biology

At the core of this system is a strain of Salmonella typhimurium, a bacterium renowned for its innate ability to home in on hypoxic, nutrient-rich tumor microenvironments. Leveraging this natural homing instinct, the research team has engineered the bacteria to transport a picornavirus stealthily into solid tumors. Once inside the tumor’s interior, the bacteria invade cancerous cells and undergo programmed lysis, releasing the viral RNA payload precisely where it is most effective. This clever Trojan horse strategy not only ensures precise localization of the virus but also maximizes its oncolytic potential by circumventing systemic immune defenses that commonly neutralize free viruses in circulation.

One of the critical impediments to effective oncolytic viral therapy is the host immune system’s pre-existing immunity to common viruses, which often results in rapid neutralization of therapeutic viruses before they reach tumor sites. The CAPPSID platform ingeniously addresses this limitation by using bacteria as protective carriers. These bacteria cloak the virus from neutralizing antibodies encountered in the bloodstream, allowing the viral payload to reach the tumor intact. This mechanism promises to extend the clinical applicability of viral therapies to patients who have pre-existing immunity, a patient population that has historically presented significant challenges for oncolytic virus therapeutics.

The engineered bacteria-virus consortium creates a sophisticated interdependent system. The virus’s replication and maturation processes are engineered to rely on a specific bacterial enzyme—a protease—that is exclusively present within the tumor environment where the engineered bacteria reside. This molecular dependency restricts viral propagation to the vicinity of the tumor, effectively locking viral replication to the tumor microenvironment and preventing deleterious spread to healthy tissues. This safety mechanism is a substantial advancement in addressing concerns about off-target infection and systemic toxicity that have hindered past approaches using live viruses in cancer therapy.

In vitro studies and mouse model experiments conducted by the Synthetic Biological Systems Lab have demonstrated the feasibility and efficacy of this dual-organism therapeutic platform. Microscopic imaging vividly illustrates the interplay, revealing Salmonella cells (stained magenta) infiltrating cancerous small cell lung carcinoma cells (grey), while the engineered picornavirus (depicted in cyan) radiates outward in a circular pattern as it propagates from the initial locus of infection. These results highlight the capacity for the system to permeate tumors and deliver a localized, amplified oncolytic effect with precise spatial control.

The interdisciplinary collaboration was led by Tal Danino, associate professor of biomedical engineering at Columbia Engineering, with vital contributions from virologist Charles M. Rice of The Rockefeller University. Their convergence of expertise in bacterial engineering and synthetic virology enabled the meticulous design of the CAPPSID system to balance therapeutic potency with safeguards that mitigate risks associated with live microbial therapies. The partnership exemplifies a new paradigm in cancer treatment research, focusing on engineering multi-organism therapies rather than single-agent interventions.

Beyond its therapeutic potential, the CAPPSID platform represents an adaptable scaffold for future development. The research team is actively pursuing extensions of this technology across a diverse array of tumor types, utilizing different viral vectors and bacterial strains to optimize efficacy and safety profiles. Their vision includes assembling a modular toolkit of engineered viruses capable of sensing intracellular environments and responding with bespoke therapeutic payloads. Moreover, by integrating bacterial strains already proven safe in clinical trials, the team aims to facilitate translational pathways that bring this promising therapy closer to human application.

A notable advantage of this system is its potential to overcome the challenges posed by tumor heterogeneity and physical barriers within solid malignancies. The combination of bacterial tropism and viral replication capacity enables deep penetration and widespread viral dissemination throughout tumors, a feat difficult to achieve with either bacteria or viruses alone. This dual delivery methodology could markedly improve therapeutic indices and reduce the chance of therapeutic resistance by promoting a multifaceted oncolytic effect.

Ensuring patient safety in therapies involving live microorganisms is paramount. CAPPSID’s unique safeguard—the requirement for a bacterial protease to activate viral maturation—adds a critical layer of biological containment. By tying viral life cycle progression to bacterial presence, the therapy effectively quarantines viral proliferation within the tumor microenvironment. This engineered dependency may serve as a blueprint for future microbiome-based therapies where tight spatial and functional control is essential.

The promising preclinical results position CAPPSID at the forefront of synthetic biology applications in oncology. As the research progresses from bench to bedside, rigorous clinical trials will be necessary to evaluate safety, dosing strategies, and therapeutic efficacy in human patients. The team’s commitment to clinical translation emphasizes the potential of living medicines that harness engineered microbial consortia to revolutionize cancer treatment paradigms.

In conjunction with advancing therapeutic design, the research group has filed a patent application to protect intellectual property surrounding their novel bacteria-virus system. Their work signals a transformative step toward realizing living therapies that orchestrate complex, cooperative interactions between multiple microorganisms to achieve precision targeting and controlled therapeutic action within cancerous tissues. This innovation may well herald a new era in bioengineered cancer therapeutics where the convergence of microbiology, synthetic biology, and oncology delivers unprecedented clinical outcomes.

With growing interest in oncolytic viruses and bacterial therapies independently, CAPPSID offers a trailblazing strategy that maximizes the intrinsic strengths of both modalities. As research evolves, it holds promise not only for improved treatment of solid tumors but also for the broader design of multi-microbial systems capable of tackling complex diseases. This synergy between engineered prokaryotes and viruses represents a bold leap forward in biomedical engineering, potentially overcoming key limitations that have constrained previous monotherapies.

Subject of Research: Engineered bacteria and viruses cooperating for targeted cancer therapy
Article Title: Engineered bacteria launch and control an oncolytic virus
News Publication Date: 15-Aug-2025
Web References:

• https://www.nature.com/articles/s41551-025-01476-8
• http://daninolab.nyc
• https://www.engineering.columbia.edu/faculty-staff/directory/tal-danino
• https://www.bme.columbia.edu/
• https://www.cancer.columbia.edu
• https://www.cuimc.columbia.edu
• https://datascience.columbia.edu
  Image Credits: Danino Lab
  Keywords: Biomedical engineering, oncolytic virus therapy, synthetic biology, bacterial cancer therapy, tumor targeting, Salmonella typhimurium, viral delivery systems, cancer treatment innovation